Zhejiang Starry Pharmaceutical Co Ltd
SSE:603520
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zhejiang Starry Pharmaceutical Co Ltd
Revenue
Zhejiang Starry Pharmaceutical Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zhejiang Starry Pharmaceutical Co Ltd
SSE:603520
|
Revenue
¥2.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Revenue
¥15B
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Revenue
¥32.6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Revenue
¥41.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Revenue
¥22.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
19%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Revenue
¥5.8B
|
CAGR 3-Years
94%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
Zhejiang Starry Pharmaceutical Co Ltd
Glance View
Zhejiang Starry Pharmaceutical Co., Ltd. engages in the research, development, manufacture, and sale of active ingredient and intermediate X-CT non-ionic contrast agent and fluoroquinolones series. The company is headquartered in Taizhou, Zhejiang and currently employs 1,818 full-time employees. The company went IPO on 2016-03-09. The X-ray contrast medium's major product is iohexol active pharmaceutical ingredient. Quinolone antimicrobial agents' major products are levofloxacin hydrochloride active pharmaceutical ingredient and levofloxacin hemihydrates active pharmaceutical ingredient.
See Also
What is Zhejiang Starry Pharmaceutical Co Ltd's Revenue?
Revenue
2.4B
CNY
Based on the financial report for Sep 30, 2025, Zhejiang Starry Pharmaceutical Co Ltd's Revenue amounts to 2.4B CNY.
What is Zhejiang Starry Pharmaceutical Co Ltd's Revenue growth rate?
Revenue CAGR 5Y
12%
Over the last year, the Revenue growth was 1%. The average annual Revenue growth rates for Zhejiang Starry Pharmaceutical Co Ltd have been 5% over the past three years , 12% over the past five years .
